Crossfire Oncology
1 known investors
Crossfire Oncology develops kinase-targeting cancer drugs using three approaches: inhibitors, degraders, and degrader antibody conjugates. The company focuses on oncology therapeutics aimed at treating cancer patients.
Investors · 1
Frequently asked questions
- What does Crossfire Oncology do?
- Crossfire Oncology develops kinase-targeting cancer drugs using three approaches: inhibitors, degraders, and degrader antibody conjugates. The company focuses on oncology therapeutics aimed at treating cancer patients.
- Who are Crossfire Oncology's investors?
- Crossfire Oncology's investors include BOM.